CDX-1140 Demonstrates Clinical and Biological Activity in Patients with Advanced Solid Tumors in Phase 1 Dose Escalation Study

    NEXT STORY
    Centrexion Therapeutics Announces CNTX-4975 Data Presentations at the 2019 American College of Rheumatology Annual Meeting and the 2019 American Academy of Physical Medicine and Rehabilitation Annual Assembly
    PREV STORY
    Neon Therapeutics Announces Updated Data Presented at Society for Immunotherapy of Cancer (SITC) Annual Meeting
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Axiom Presenting “Simplifying the Complex Data and Operational Awareness Needs of Oncology Studies Using Unified eClinical Tech” at Clinical Operations in Oncology Trials USA 2020: A Virtual Experience

    author_avatar
    NASDAQ Market News

    Immune Health Supplements Market Exhibit 7.4% CAGR and Hit USD 29.40 Billion till 2027; Rapid Changes in Lifestyles to Bolster Growth, says Fortune Business Insights™

    author_avatar
    NASDAQ Market News

    Blueberries Medical Reports 2021 Q2 Financial Results and Provides Corporate and Operations Update

    author_avatar
    NASDAQ Market News